Across TCGA pan-cancer cohorts, DEFB132 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DEFB132 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher DEFB132 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB132 expression acts as an unfavorable survival marker.

SKCM and LUSC are the cancer types where DEFB132 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	III,IV	0.072	0.814	<.001	20	view →
LUSC	DFS	Median	All	0.064	0.791	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: DEFB132 tumor-vs-normal RNA expression · all DEFB132 data types